Evercore ISI raised the firm’s price target on Guardant Health (GH) to $110 from $105 and keeps an In Line rating on the shares. Guardant initiated “conservative” 2026 guidance considering the “catalyst rich” second half that is ahead, the analyst tells investors.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GH:
- Guardant Health price target raised to $130 from $120 at JPMorgan
- Guardant Health price target raised to $145 from $140 at BTIG
- Guardant Health price target raised to $130 from $120 at Stifel
- Guardant Health price target raised to $135 from $125 at Canaccord
- Guardant Health price target raised to $150 from $135 at Citi